Pathology: mGC or mGEJC - L2 - all population; mGC or mGEJC - L2 - PDL1 positive;
mGC or mGEJC - L2 - all population | mGC or mGEJC - L2 - PDL1 positive | |||||
JAVELIN Gastric 300, 2018 | CA184-162, 2017 | ATTRACTION-2 (Kang), 2017 | KEYNOTE-061 (all population), 2018 | KEYNOTE-061 (PDL1 CPS>1), 2018 | ||
pembrolizumab alone | 2 | T1 | T1 | |||
avelumab alone | 1 | T1 | ||||
Ipilimumab (10 mg/kg) | 1 | T1 | ||||
nivolumab alone | 1 | T1 | ||||
paclitaxel | 0 | T0 | T0 | |||
Standard of Care (SoC) | 0 | T0 | T0 | |||
placebo | 0 | T0 |